‘As a clinician when I go to a lecture and see someone presenting cases, I want to see the literature behind their decision-making process – it’s how I learn’

How did you become a KoL?

I worked in a practice that used the SureSmile Aligner system and had to finish cases the previous orthodontist had started. That meant I had to quickly learn the platform, the science behind it and the way it worked. It is a system that has a number of layers and for the beginner can be daunting given the complexities, which meant I had a lot of questions – and some doubts. To calm these doubts and answer these questions, I approached the team in the US to find out more – I sent them cases, worked through their intricacies and tried to approach my work in a different way while ensuring the best outcome for the patient.

Throughout this process, I was contacted by a member of the Dentsply Sirona team in Spain to deliver a lecture, asking me to share my clinical experience. I remember it well because they said they didn’t want me to sell the system, they wanted me to be honest about my experience and knowledge. Given I had some doubts about the system, it meant I knew where the weak points were, things that could be improved and areas where other systems were better. I was adamant that if someone asked me about these weaknesses, there was no way I could not talk about them, and so it was reassuring to know I could do this. Our goal is to improve the oral health of our patients, and part of that means being honest.

As a KoL, I believe it’s important to also reflect on other systems within the field and work with those too. Again, I’m encouraged to do this – it is the only way we as practitioners will improve the service we offer our patients.

Is that something you enjoy – being able to look across the board at different systems and use their clinical knowledge you have to choose what works best for you and therefore for your patients?

Yes, absolutely. It’s very important not to forget we are the clinicians, and that commercial teams and brands take advice from us, not the other way around. One brand I used to work with, for example, gave me a feeling of being obligated to work with them and them only, which made me feel uncomfortable and should make any clinician and KoL feel uncomfortable. The more cases we did with them, the better the reward for the clinician, which again made me feel uncomfortable. Treating patients isn’t a race and isn’t about getting higher rewards – I want to give my patient all the necessary information to make the best, most informed decision about their treatment. That could be choosing fixed appliances rather aligners because they’re not able to or willing to meet the oral health demands their treatment entails – it does not mean selling a brand because I have financial incentives to do so.

How important does this make science and peer-reviewed research in deciding what treatments to offer patients?

It’s hugely important. Good science is good science, and that is separate and independent of me being a KoL and working with a brand. As a clinician when I go to a lecture and see someone presenting cases, I want to see the literature behind their decision-making process – it’s how I learn and it’s how our profession reflects and improves. When I am delivering a lecture, I always try to search for and include references for the audience so they can see why I took the decisions I did. In orthodontics research is evolving at such a pace that a presentation from four or five years ago could have references that are out of date already!

We also face the scenario where a significant proportion of literature in orthodontics on aligners is based on Invisalign, and these aligners are unique – SureSmile, for example, uses a different material to that of Invisalign, so we have to be very careful of using literature within presentations and references that confuses the two. This will obviously come – and we’re carrying out some research at the moment to gather some of these data, but as you know this takes an incredible amount of time.

Does that research takes on additional importance given the growing trend of patients coming to the clinic demanding a treatment they’ve seen and decided they want. How much of a problem is this dynamic?

You’ve just opened up a big wound of mine! In the last two years in Spain, there’s a boom in the number of orthodontic clinics promising patients fast results at below-market prices that don’t have orthodontists on site – they only have a dental hygienist or dental therapist who give the aligners to the patient. They’re branching out into shopping malls where you can see an orthodontist, too. What it means is patients are looking at orthodontic as if it is whitening – a total optional extra – and they don’t want to fix their underlying problems. They look at it purely from an aesthetic point of view.

There are still too many patients who are undergoing unsafe treatment, and so it will take time for patients to realise they’re not getting the attention their oral health needs with no oversight from an orthodontist.

In Barcelona where in practice, last year there were 10 new clinics popping up whose prices are low and have aggressive marketing campaign. During this time, while I had a healthy flow of patients, I would refuse to treat them the way these clinics had promised – which often involved the removal of healthy teeth or the filing down of natural healthy teeth – which meant my prices were higher, personalised care plans were longer and required a higher level of compliance. I would say maybe one in five patients understood these, but unfortunately the rest did not. I prefer not to treat these patients – they come to the practice with unrealistic expectations about their treatment, and often give the impression they know more than we do!

Is it going to get worse?

I think there are signs of improvement. I have patients who last year come in for a first visit and consultation, went through their treatment elsewhere, and have now come back to undergo treatment with me to correct the issues we identified at the consultation, plus to fix problems caused by the alternative treatment they chose. There are still too many patients who are undergoing unsafe treatment, and so it will take time for patients to realise they’re not getting the attention their oral health needs with no oversight from an orthodontist. Unfortunately, these patients are experiencing problems, realising there’s no-one available to address them, so are having to find alternative orthodontists to solve their problems.

I really hope patients will see through the differences between quick fix treatment and between treatment that is thorough, longer but to their benefit. As clinicians, it is also on us to educate patients as much as possible about the pitfalls.

What advice would you give to students starting out their journey?

The first thing I would say is that AI is not going to replace us – that’s what everyone is talking about right now! I believe it will be more assisted intelligence, assisting us clinicians in what we do, not replacing what we do.

If you’re looking for a career in orthodontics, it sounds simple, but I would say study, and study hard. The aligner world might seem easy and provide an easy source of income, but it’s way more complicated than fixed appliances, and they are the future of orthodontics, so if you want to control the treatment, you need to understand the science.

Finally, don’t let commercial brands – whether you go on to become a KoL or not – dominate the conversation and direction our profession goes in. We trained clinicians have the knowledge, and we treat the patients. Share your clinician experience without selling the product – if you’re a good clinician and you do excellent dentistry, the products you use will sell themselves. Remember, patients are not customers – they will always be patients who defer to our knowledge, not customers who want to be sold to. It’s a small difference, but it will really change the way you view your job.

Related Articles

Energy metabolism in health and diseases

Energy metabolism is indispensable for sustaining physiological functions in living organisms and assumes a pivotal role across physiological and pathological conditions. This review provides an extensive overview of advancements in energy metabolism research, elucidating critical pathways such as glycolysis, oxidative phosphorylation, fatty acid metabolism, and amino acid metabolism, along with their intricate regulatory mechanisms. The homeostatic balance of these processes is crucial; however, in pathological states such as neurodegenerative diseases, autoimmune disorders, and cancer, extensive metabolic reprogramming occurs, resulting in impaired glucose metabolism and mitochondrial dysfunction, which accelerate disease progression. Recent investigations into key regulatory pathways, including mechanistic target of rapamycin, sirtuins, and adenosine monophosphate-activated protein kinase, have considerably deepened our understanding of metabolic dysregulation and opened new avenues for therapeutic innovation. Emerging technologies, such as fluorescent probes, nano-biomaterials, and metabolomic analyses, promise substantial improvements in diagnostic precision. This review critically examines recent advancements and ongoing challenges in metabolism research, emphasizing its potential for precision diagnostics and personalized therapeutic interventions. Future studies should prioritize unraveling the regulatory mechanisms of energy metabolism and the dynamics of intercellular energy interactions. Integrating cutting-edge gene-editing technologies and multi-omics approaches, the development of multi-target pharmaceuticals in synergy with existing therapies such as immunotherapy and dietary interventions could enhance therapeutic efficacy. Personalized metabolic analysis is indispensable for crafting tailored treatment protocols, ultimately providing more accurate medical solutions for patients. This review aims to deepen the understanding and improve the application of energy metabolism to drive innovative diagnostic and therapeutic strategies.

Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets

Macrophages are immune cells belonging to the mononuclear phagocyte system. They play crucial roles in immune defense, surveillance, and homeostasis. This review systematically discusses the types of hematopoietic progenitors that give rise to macrophages, including primitive hematopoietic progenitors, erythro-myeloid progenitors, and hematopoietic stem cells. These progenitors have distinct genetic backgrounds and developmental processes. Accordingly, macrophages exhibit complex and diverse functions in the body, including phagocytosis and clearance of cellular debris, antigen presentation, and immune response, regulation of inflammation and cytokine production, tissue remodeling and repair, and multi-level regulatory signaling pathways/crosstalk involved in homeostasis and physiology. Besides, tumor-associated macrophages are a key component of the TME, exhibiting both anti-tumor and pro-tumor properties. Furthermore, the functional status of macrophages is closely linked to the development of various diseases, including cancer, autoimmune disorders, cardiovascular disease, neurodegenerative diseases, metabolic conditions, and trauma. Targeting macrophages has emerged as a promising therapeutic strategy in these contexts. Clinical trials of macrophage-based targeted drugs, macrophage-based immunotherapies, and nanoparticle-based therapy were comprehensively summarized. Potential challenges and future directions in targeting macrophages have also been discussed. Overall, our review highlights the significance of this versatile immune cell in human health and disease, which is expected to inform future research and clinical practice.

Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines

The successful approval of peptide-based drugs can be attributed to a collaborative effort across multiple disciplines. The integration of novel drug design and synthesis techniques, display library technology, delivery systems, bioengineering advancements, and artificial intelligence have significantly expedited the development of groundbreaking peptide-based drugs, effectively addressing the obstacles associated with their character, such as the rapid clearance and degradation, necessitating subcutaneous injection leading to increasing patient discomfort, and ultimately advancing translational research efforts. Peptides are presently employed in the management and diagnosis of a diverse array of medical conditions, such as diabetes mellitus, weight loss, oncology, and rare diseases, and are additionally garnering interest in facilitating targeted drug delivery platforms and the advancement of peptide-based vaccines. This paper provides an overview of the present market and clinical trial progress of peptide-based therapeutics, delivery platforms, and vaccines. It examines the key areas of research in peptide-based drug development through a literature analysis and emphasizes the structural modification principles of peptide-based drugs, as well as the recent advancements in screening, design, and delivery technologies. The accelerated advancement in the development of novel peptide-based therapeutics, including peptide-drug complexes, new peptide-based vaccines, and innovative peptide-based diagnostic reagents, has the potential to promote the era of precise customization of disease therapeutic schedule.

Probabilistic machine learning for battery health diagnostics and prognostics—review and perspectives

Diagnosing lithium-ion battery health and predicting future degradation is essential for driving design improvements in the laboratory and ensuring safe and reliable operation over a product’s expected lifetime. However, accurate battery health diagnostics and prognostics is challenging due to the unavoidable influence of cell-to-cell manufacturing variability and time-varying operating circumstances experienced in the field. Machine learning approaches informed by simulation, experiment, and field data show enormous promise to predict the evolution of battery health with use; however, until recently, the research community has focused on deterministic modeling methods, largely ignoring the cell-to-cell performance and aging variability inherent to all batteries. To truly make informed decisions regarding battery design in the lab or control strategies for the field, it is critical to characterize the uncertainty in a model’s predictions. After providing an overview of lithium-ion battery degradation, this paper reviews the current state-of-the-art probabilistic machine learning models for health diagnostics and prognostics. Details of the various methods, their advantages, and limitations are discussed in detail with a primary focus on probabilistic machine learning and uncertainty quantification. Last, future trends and opportunities for research and development are discussed.

Landscape of small nucleic acid therapeutics: moving from the bench to the clinic as next-generation medicines

The ability of small nucleic acids to modulate gene expression via a range of processes has been widely explored. Compared with conventional treatments, small nucleic acid therapeutics have the potential to achieve long-lasting or even curative effects via gene editing. As a result of recent technological advances, efficient small nucleic acid delivery for therapeutic and biomedical applications has been achieved, accelerating their clinical translation. Here, we review the increasing number of small nucleic acid therapeutic classes and the most common chemical modifications and delivery platforms. We also discuss the key advances in the design, development and therapeutic application of each delivery platform. Furthermore, this review presents comprehensive profiles of currently approved small nucleic acid drugs, including 11 antisense oligonucleotides (ASOs), 2 aptamers and 6 siRNA drugs, summarizing their modifications, disease-specific mechanisms of action and delivery strategies. Other candidates whose clinical trial status has been recorded and updated are also discussed. We also consider strategic issues such as important safety considerations, novel vectors and hurdles for translating academic breakthroughs to the clinic. Small nucleic acid therapeutics have produced favorable results in clinical trials and have the potential to address previously “undruggable” targets, suggesting that they could be useful for guiding the development of additional clinical candidates.

Responses

Your email address will not be published. Required fields are marked *